• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sana Biotechnology Inc (NQ: SANA )

    3.005 -0.095 (-3.06%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sana Biotechnology Inc

    < Previous 1 2 Next >
    Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at September 2024 Investor Conferences
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at May and June 2024 Investor Conferences
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Pricing of Upsized Public Offering
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Proposed Public Offering of Common Stock
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
    Expect to disclose initial SC262 clinical data in 2024 
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at November and December 2023 Investor Conferences
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at September 2023 Investor Conferences
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology to Present at June 2023 Investor Conferences
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
    From Sana Biotechnology, Inc
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.